Southwest Oncology Group Biorepository

描述（由申请人提供）：西南肿瘤学组生物样本库的总体目标是支持增加对高质量、注释良好的人体样本的收集、储存和访问，这些样本是从参加NCI资助的临床试验的患者人群中收集的，并代表这些患者人群。提供这种基础设施的总体科学目标是开发改进的癌症预后和预测标志物，改善分子分期，了解治疗耐药机制，鉴定新的假定治疗靶点，并开发新的治疗策略。这些目标是通过基础广泛的多学科努力来实现的，这些努力依赖于获得来自不同人群的高质量、特征良好的生物标本，并汇集了SWOG成员及其附属机构以及SWOG以外的个人的临床、实验室和科学专业知识。这些活动主要依靠有才能的调查人员、病理学家、生物标本库以及生物储存库与提交机构、业务办公室、统计中心、调查人员和国家癌症研究所的密切工作关系。样本将根据通过SWOG翻译科学审查过程收到的提案的科学价值发布。

DESCRIPTION (provided by applicant): The overall general goals of the Southwest Oncology Group Biospecimen Repository is to support the increased collection of, storage of and access to high-quality, well-annotated human specimens collected from and representative of the patient populations entered into NCI-funded clinical trials. The overall scientific goal in providing this infrastructure is to develop improved prognostic and predictive markers for cancer, to improve molecular staging, to understand mechanisms of treatment resistance, to identify new putative therapeutic targets, and to develop novel therapeutic strategies. These goals are addressed through broad-based multidisciplinary efforts that rely on access to high quality, well characterized biospecimens from diverse population groups and that bring together clinical, laboratory and scientific expertise from within SWOG membership and its affiliates, as well as from individuals outside of SWOG. These activities critically rely on talented investigators, pathologists, biospecimen banks and close working relationships of the biorepository with the submitting institutions, the Operations Office, Statistical Center, investigators and the NCI. Specimens will be released based on the scientific merit of the proposals received via SWOG Translation Science Review process.